{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:21:34Z","timestamp":1793726494220,"version":"4.6.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T00:00:00Z","timestamp":1760832000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T00:00:00Z","timestamp":1760832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Vivace Therapeutics, San Mateo, CA, USA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1038\/s41591-025-04029-3","type":"journal-article","created":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T14:01:56Z","timestamp":1760882516000},"page":"4281-4290","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":92,"title":["YAP\/TEAD inhibitor VT3989 in solid tumors: a phase 1\/2 trial"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2154-3309","authenticated-orcid":false,"given":"Timothy A.","family":"Yap","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Kwiatkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibiayi","family":"Dagogo-Jack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7959-3018","authenticated-orcid":false,"given":"Michael","family":"Offin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjorie G.","family":"Zauderer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1599-7494","authenticated-orcid":false,"given":"Robert","family":"Kratzke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4246-9344","authenticated-orcid":false,"given":"Jayesh","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Body","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Millward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony W.","family":"Tolcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1311-4173","authenticated-orcid":false,"given":"Kanwal P. S.","family":"Raghav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archie","family":"Thurston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Len","family":"Post","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7367-1419","authenticated-orcid":false,"given":"F. Andrew","family":"Dorr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy T.","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelesh","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedy L.","family":"Kindler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,19]]},"reference":[{"key":"4029_CR1","doi-asserted-by":"publisher","unstructured":"Harvey, K. F. & Tang, T. T. Targeting the Hippo pathway in cancer. Nat. Rev. Drug Discov. https:\/\/doi.org\/10.1038\/s41573-025-01234-0 (2025).","DOI":"10.1038\/s41573-025-01234-0"},{"key":"4029_CR2","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami, E. et al. The cBio Cancer Genomics Portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401\u2013404 (2012).","journal-title":"Cancer Discov."},{"key":"4029_CR3","first-page":"pl1","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1 (2013).","journal-title":"Sci. Signal."},{"key":"4029_CR4","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","volume":"173","author":"F Sanchez-Vega","year":"2018","unstructured":"Sanchez-Vega, F. et al. Oncogenic signaling pathways in The Cancer Genome Atlas. Cell 173, 321\u2013337 (2018).","journal-title":"Cell"},{"key":"4029_CR5","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.celrep.2018.10.001","volume":"25","author":"Y Wang","year":"2018","unstructured":"Wang, Y. et al. Comprehensive molecular characterization of the Hippo signaling pathway in cancer. Cell Rep. 25, 1304\u20131317 (2018).","journal-title":"Cell Rep."},{"key":"4029_CR6","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1158\/0008-5472.CAN-10-2164","volume":"71","author":"H Murakami","year":"2011","unstructured":"Murakami, H. et al. LATS2 is a tumor suppressor gene of malignant mesothelioma. Cancer Res. 71, 873\u2013883 (2011).","journal-title":"Cancer Res."},{"key":"4029_CR7","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/ng0294-180","volume":"6","author":"MH Ruttledge","year":"1994","unstructured":"Ruttledge, M. H. et al. Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nat. Genet. 6, 180\u2013184 (1994).","journal-title":"Nat. Genet."},{"key":"4029_CR8","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3892\/br.2025.1934","volume":"22","author":"EK Dwianingsih","year":"2025","unstructured":"Dwianingsih, E. K., Krisnugraha, Y. P., Bawono, R. G. & Malueka, R. G. Molecular biomarkers in meningioma (Review). Biomed. Rep. 22, 56 (2025).","journal-title":"Biomed. Rep."},{"key":"4029_CR9","doi-asserted-by":"crossref","DOI":"10.3389\/ftox.2023.1161995","volume":"5","author":"Y Sekido","year":"2023","unstructured":"Sekido, Y. & Sato, T. NF2 alteration in mesothelioma. Front. Toxicol. 5, 1161995 (2023).","journal-title":"Front. Toxicol."},{"key":"4029_CR10","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","volume":"48","author":"R Bueno","year":"2016","unstructured":"Bueno, R. et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat. Genet. 48, 407\u2013416 (2016).","journal-title":"Nat. Genet."},{"key":"4029_CR11","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1038\/s41416-022-01979-0","volume":"127","author":"S Hiltbrunner","year":"2022","unstructured":"Hiltbrunner, S. et al. Genomic landscape of pleural and peritoneal mesothelioma tumours. Br. J. Cancer 127, 1997\u20132005 (2022).","journal-title":"Br. J. Cancer"},{"key":"4029_CR12","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","volume":"8","author":"J Hmeljak","year":"2018","unstructured":"Hmeljak, J. et al. Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov. 8, 1548\u20131565 (2018).","journal-title":"Cancer Discov."},{"key":"4029_CR13","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1440-1827.2011.02666.x","volume":"61","author":"Y Sekido","year":"2011","unstructured":"Sekido, Y. Inactivation of Merlin in malignant mesothelioma cells and the Hippo signaling cascade dysregulation. Pathol. Int. 61, 331\u2013344 (2011).","journal-title":"Pathol. Int."},{"key":"4029_CR14","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/JTO.0000000000000493","volume":"10","author":"A Miyanaga","year":"2015","unstructured":"Miyanaga, A. et al. Hippo pathway gene mutations in malignant mesothelioma: revealed by RNA and targeted exon sequencing. J. Thorac. Oncol. 10, 844\u2013851 (2015).","journal-title":"J. Thorac. Oncol."},{"key":"4029_CR15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114725","volume":"211","author":"T Tang","year":"2024","unstructured":"Tang, T. et al. PB195: Evaluating the use of Merlin-YAP dual-label immunohistochemistry for predicting response to TEAD inhibitor VT3989. Eur. J. Cancer 211, 114725 (2024).","journal-title":"Eur. J. Cancer"},{"key":"4029_CR16","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ydbio.2020.12.018","volume":"475","author":"F Szulzewsky","year":"2021","unstructured":"Szulzewsky, F., Holland, E. C. & Vasioukhin, V. YAP1 and its fusion proteins in cancer initiation, progression and therapeutic resistance. Dev. Biol. 475, 205\u2013221 (2021).","journal-title":"Dev. Biol."},{"key":"4029_CR17","doi-asserted-by":"publisher","unstructured":"Guo, S. et al. VGLL2 and TEAD1 fusion proteins identified in human sarcoma drive YAP\/TAZ-independent tumorigenesis by engaging EP300. Elife https:\/\/doi.org\/10.7554\/eLife.98386 (2025).","DOI":"10.7554\/eLife.98386"},{"key":"4029_CR18","doi-asserted-by":"crossref","first-page":"100170","DOI":"10.1016\/j.esmoop.2021.100170","volume":"6","author":"S Stacchiotti","year":"2021","unstructured":"Stacchiotti, S. et al. Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts. ESMO Open 6, 100170 (2021).","journal-title":"ESMO Open"},{"key":"4029_CR19","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1042\/CS20201474","volume":"136","author":"R Cunningham","year":"2022","unstructured":"Cunningham, R. & Hansen, C. G. The Hippo pathway in cancer: YAP\/TAZ and TEAD as therapeutic targets in cancer. Clin. Sci. (Lond.) 136, 197\u2013222 (2022).","journal-title":"Clin. Sci. (Lond.)"},{"key":"4029_CR20","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41573-020-0070-z","volume":"19","author":"A Dey","year":"2020","unstructured":"Dey, A., Varelas, X. & Guan, K.-L. Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine. Nat. Rev. Drug Discov. 19, 480\u2013494 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"4029_CR21","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.str.2015.11.005","volume":"24","author":"CL Noland","year":"2016","unstructured":"Noland, C. L. et al. Palmitoylation of TEAD transcription factors is required for their stability and function in Hippo pathway signaling. Structure 24, 179\u2013186 (2016).","journal-title":"Structure"},{"key":"4029_CR22","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.str.2015.09.009","volume":"23","author":"AV Pobbati","year":"2015","unstructured":"Pobbati, A. V. et al. Targeting the central pocket in human transcription factor TEAD as a potential cancer therapeutic strategy. Structure 23, 2076\u20132086 (2015).","journal-title":"Structure"},{"key":"4029_CR23","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nchembio.2036","volume":"12","author":"P Chan","year":"2016","unstructured":"Chan, P. et al. Autopalmitoylation of TEAD proteins regulates transcriptional output of the Hippo pathway. Nat. Chem. Biol. 12, 282\u2013289 (2016).","journal-title":"Nat. Chem. Biol."},{"key":"4029_CR24","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1158\/1535-7163.MCT-20-0717","volume":"20","author":"TT Tang","year":"2021","unstructured":"Tang, T. T. et al. Small molecule inhibitors of TEAD auto-palmitoylation selectively inhibit proliferation and tumor growth of NF2-deficient mesothelioma. Mol. Cancer Ther. 20, 986\u2013998 (2021).","journal-title":"Mol. Cancer Ther."},{"key":"4029_CR25","first-page":"402","volume":"69","author":"M Carbone","year":"2019","unstructured":"Carbone, M. et al. Mesothelioma: scientific clues for prevention, diagnosis, and therapy. CA Cancer J. Clin. 69, 402\u2013429 (2019).","journal-title":"CA Cancer J. Clin."},{"key":"4029_CR26","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1200\/JCO-24-02425","volume":"43","author":"HL Kindler","year":"2025","unstructured":"Kindler, H. L. et al. Treatment of pleural mesothelioma: ASCO guideline update. J. Clin. Oncol. 43, 1006\u20131038 (2025).","journal-title":"J. Clin. Oncol."},{"key":"4029_CR27","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.lungcan.2014.03.006","volume":"84","author":"MG Zauderer","year":"2014","unstructured":"Zauderer, M. G. et al. Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma. Lung Cancer 84, 271\u2013274 (2014).","journal-title":"Lung Cancer"},{"key":"4029_CR28","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S1470-2045(22)00061-4","volume":"23","author":"HL Kindler","year":"2022","unstructured":"Kindler, H. L. et al. Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial. Lancet Oncol. 23, 540\u2013552 (2022).","journal-title":"Lancet Oncol."},{"key":"4029_CR29","doi-asserted-by":"crossref","first-page":"101432","DOI":"10.1016\/j.eclinm.2022.101432","volume":"48","author":"DA Fennell","year":"2022","unstructured":"Fennell, D. A. et al. Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): a randomised, phase 2 trial. EClinicalMedicine 48, 101432 (2022).","journal-title":"EClinicalMedicine"},{"key":"4029_CR30","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.jtho.2018.04.034","volume":"13","author":"SG Armato 3rd","year":"2018","unstructured":"Armato, S. G. 3rd& Nowak, A. K. Revised modified Response Evaluation Criteria in Solid Tumors for assessment of response in malignant pleural mesothelioma (version 1.1). J. Thorac. Oncol. 13, 1012\u20131021 (2018).","journal-title":"J. Thorac. Oncol."},{"key":"4029_CR31","doi-asserted-by":"crossref","first-page":"7282","DOI":"10.1158\/1538-7445.AM2024-7282","volume":"84","author":"TT Tang","year":"2024","unstructured":"Tang, T. T. & Post, L. Abstract 7282: Comparing TEAD palmitoylation inhibitors with differential TEAD selectivity in combination efficacy with targeted therapies and in renal safety. Cancer Res. 84, 7282 (2024).","journal-title":"Cancer Res."},{"key":"4029_CR32","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2131\/jts.49.175","volume":"49","author":"H Otsuki","year":"2024","unstructured":"Otsuki, H. et al. Reversible and monitorable nephrotoxicity in rats by the novel potent transcriptional enhanced associate domain (TEAD) inhibitor, K-975. J. Toxicol. Sci. 49, 175\u2013191 (2024).","journal-title":"J. Toxicol. Sci."},{"key":"4029_CR33","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1681\/ASN.2014090916","volume":"27","author":"M Schwartzman","year":"2016","unstructured":"Schwartzman, M. et al. Podocyte-specific deletion of Yes-associated protein causes FSGS and progressive renal failure. J. Am. Soc. Nephrol. 27, 216\u2013226 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"4029_CR34","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1681\/ASN.2020020220","volume":"31","author":"JJ Chung","year":"2020","unstructured":"Chung, J. J. et al. Single-cell transcriptome profiling of the kidney glomerulus identifies key cell types and reactions to injury. J. Am. Soc. Nephrol. 31, 2341\u20132354 (2020).","journal-title":"J. Am. Soc. Nephrol."},{"key":"4029_CR35","doi-asserted-by":"crossref","first-page":"F419","DOI":"10.1152\/ajprenal.00426.2021","volume":"322","author":"J Chen","year":"2022","unstructured":"Chen, J., Wang, X., He, Q. & Harris, R. C. TAZ is important for maintenance of the integrity of podocytes. Am. J. Physiol. Ren. Physiol. 322, F419\u2013F428 (2022).","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"4029_CR36","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aaf8165","volume":"10","author":"MM Rinschen","year":"2017","unstructured":"Rinschen, M. M. et al. YAP-mediated mechanotransduction determines the podocyte\u2019s response to damage. Sci. Signal. 10, eaaf8165 (2017).","journal-title":"Sci. Signal."},{"key":"4029_CR37","doi-asserted-by":"crossref","first-page":"600","DOI":"10.3390\/cells8060600","volume":"8","author":"HD Huh","year":"2019","unstructured":"Huh, H. D., Kim, D. H., Jeong, H. S. & Park, H. W. Regulation of TEAD transcription factors in cancer biology. Cells 8, 600 (2019).","journal-title":"Cells"},{"key":"4029_CR38","doi-asserted-by":"crossref","first-page":"5913","DOI":"10.1158\/1538-7445.AM2024-5913","volume":"84","author":"F Muller","year":"2024","unstructured":"Muller, F., Kunnimalaiyaan, S., Mangrolia, P. & Olson, J. Abstract 5913: TEAD1\/4 inhibitors exhibit deeper biological impact and broader activity compared to TEAD1-only inhibitors in both monotherapy and combination without additional kidney toxicity. Cancer Res. 84, 5913 (2024).","journal-title":"Cancer Res."},{"key":"4029_CR39","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/ng.3218","volume":"47","author":"L Lin","year":"2015","unstructured":"Lin, L. et al. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat. Genet. 47, 250\u2013256 (2015).","journal-title":"Nat. Genet."},{"key":"4029_CR40","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-13771-5","volume":"11","author":"T Tsuji","year":"2020","unstructured":"Tsuji, T. et al. YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation. Nat. Commun. 11, 74 (2020).","journal-title":"Nat. Commun."},{"key":"4029_CR41","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ccell.2019.12.006","volume":"37","author":"KJ Kurppa","year":"2020","unstructured":"Kurppa, K. J. et al. Treatment-induced tumor dormancy through YAP-mediated transcriptional reprogramming of the apoptotic pathway. Cancer Cell 37, 104\u2013122 (2020).","journal-title":"Cancer Cell"},{"key":"4029_CR42","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz4589","volume":"12","author":"MB Nilsson","year":"2020","unstructured":"Nilsson, M. B. et al. A YAP\/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components. Sci. Transl. Med. 12, eaaz4589 (2020).","journal-title":"Sci. Transl. Med."},{"key":"4029_CR43","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-47423-0","volume":"15","author":"F Haderk","year":"2024","unstructured":"Haderk, F. et al. Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer. Nat. Commun. 15, 3741 (2024).","journal-title":"Nat. Commun."},{"key":"4029_CR44","doi-asserted-by":"crossref","first-page":"5364","DOI":"10.1158\/1538-7445.AM2022-5364","volume":"82","author":"TT Tang","year":"2022","unstructured":"Tang, T. T. & Post, L. Abstract 5364: The TEAD autopalmitoylation inhibitor VT3989 improves efficacy and increases durability of efficacy of osimertinib in preclinical EGFR mutant tumor models. Cancer Res. 82, 5364 (2022).","journal-title":"Cancer Res."},{"key":"4029_CR45","doi-asserted-by":"crossref","first-page":"B088","DOI":"10.1158\/1535-7163.TARG-23-B088","volume":"22","author":"TT Tang","year":"2023","unstructured":"Tang, T. T. & Post, L. Abstract B088: VT3989, the first-in-class and first-in-human TEAD auto-palmitoylation inhibitor, enhances the efficacy and durability of multiple targeted therapies of the MAPK and P13K\/AKT\/mTOR pathways. Mol. Cancer Ther. 22, B088 (2023).","journal-title":"Mol. Cancer Ther."},{"key":"4029_CR46","doi-asserted-by":"crossref","first-page":"4112","DOI":"10.1158\/0008-5472.CAN-23-2994","volume":"83","author":"AC Edwards","year":"2023","unstructured":"Edwards, A. C. et al. TEAD inhibition overcomes YAP1\/TAZ-driven primary and acquired resistance to KRASG12C inhibitors. Cancer Res. 83, 4112\u20134129 (2023).","journal-title":"Cancer Res."},{"key":"4029_CR47","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1158\/0008-5472.CAN-23-2729","volume":"83","author":"S Mukhopadhyay","year":"2023","unstructured":"Mukhopadhyay, S. et al. Genome-wide CRISPR screens identify multiple synthetic lethal targets that enhance KRASG12C inhibitor efficacy. Cancer Res. 83, 4095\u20134111 (2023).","journal-title":"Cancer Res."},{"key":"4029_CR48","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1158\/1535-7163.MCT-23-0371","volume":"23","author":"T Ogimoto","year":"2024","unstructured":"Ogimoto, T. et al. Combination therapy with EGFR tyrosine kinase inhibitors and TEAD inhibitor increases tumor suppression effects in EGFR mutation\u2013positive lung cancer. Mol. Cancer Ther. 23, 564\u2013576 (2024).","journal-title":"Mol. Cancer Ther."},{"key":"4029_CR49","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumors. Revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04029-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04029-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04029-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T15:59:38Z","timestamp":1765814378000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04029-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,19]]},"references-count":49,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4029"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-04029-3","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,19]]},"assertion":[{"value":"4 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.A.Y. is an employee of The University of Texas MD Anderson Cancer Center, where he is Vice President, Head of Clinical Development, in the Therapeutics Discovery Division, which has a commercial interest in DDR and other inhibitors (IACS30380\/ART0380 was licensed to Artios); has received funding paid to his institution from Acrivon, Artios, AstraZeneca, Bayer, BeiGene, BioNTech, Blueprint, Bristol Myers Squibb, Boundless Bio, Clovis, Constellation, Cyteir, Eli Lilly, EMD Serono, Forbius, F-Star, GlaxoSmithKline, Genentech, Haihe, Ideaya ImmuneSensor, Insilico Medicine, Ionis, Ipsen, Jounce, Karyopharm, KSQ, Kyowa, Merck, Mirati, Novartis, Pfizer, Ribon Therapeutics, Regeneron, Repare, Rubius, Sanofi, Scholar Rock, Seattle Genetics, Tango, Tesaro, Vivace Therapeutics and Zenith; has received consultancy funding from AbbVie, Acrivon, Adagene, Almac, Aduro, Amphista, Artios, Astex, AstraZeneca, Athena, Atrin, Avenzo, Avoro, Axiom, Baptist Health Systems, Bayer, BeiGene, BioCity Pharma, Blueprint, Boxer, Bristol Myers Squibb, C4 Therapeutics, Calithera, Cancer Research UK, Carrick Therapeutics, Circle Pharma, Clovis, Cybrexa, Daiichi-Sankyo, Dark Blue Therapeutics, Diffusion, Duke Street Bio, 858 Therapeutics, EcoR1 Capital, Ellipses Pharma, EMD Serono, Entos, F-Star, Genesis Therapeutics, Genmab, Glenmark, GLG, Globe Life Sciences, GlaxoSmithKline, Guidepoint, Ideaya Biosciences, Idience, Ignyta, I-Mab, ImmuneSensor, Impact Therapeutics, Institut Gustave Roussy, Intellisphere, Jansen, Kyn, MEI Pharma, Mereo, Merck, Merit, Monte Rosa Therapeutics, Natera, Nested Therapeutics, Nexys, Nimbus, Novocure, Odyssey, OHSU, OncoSec, Ono Pharma, Onxeo, PanAngium Therapeutics, Pegascy, Physicians\u02bc Education Resource, Pfizer, Piper-Sandler, Pliant Therapeutics, Prolynx, Radiopharma Theranostics, Repare, resTORbio, Roche, Ryvu Therapeutics, SAKK, Sanofi, Schrodinger, Servier, Synnovation, Synthis Therapeutics, Tango, TCG Crossover, TD2, Terremoto Biosciences, Tessellate Bio, Theragnostics, Terns Pharmaceuticals, Tolremo, Tome, Thryv Therapeutics, Trevarx Biomedical, Varian, Veeva, Versant, Vibliome, Voronoi, Xinthera, Zai Labs and ZielBio; and is a stockholder in Seagen. He was supported by National Cancer Institute Cancer Center Support Grant CA016672 to The University of Texas MD Anderson Cancer Center; US Department of Defense grants W81XWH2210504_BC211174 and W81XWH-21-1-0282_OC200482; V Foundation Scholar Grant VC2020-001; and National Institutes of Health R01 grant 1R01CA255074. D.J.K. has research contracts with Genentech, AADI and Revolution Medicines and is a consultant to Genentech, AADI, Expertconnect, Guidepoint, Bridgebio, Slingshot Insights, William Blair, MEDACorp and Radyus Research. I.D.-J. has advisory roles with AstraZeneca, Bayer, BostonGene, Bristol Myers Squibb, Catalyst, Eli Lilly, Genentech, Janssen, Merus, Novocure, Pfizer, Sanofi\/Genzyme and Thermo Fisher Scientific and has received research funding from Array, BostonGene, Genentech, Novartis and Pfizer. M.O. has consulting roles with\/honoraria from Novartis, Jazz Pharmaceuticals, Pfizer, Targeted Oncology, OncLive, the American Society for Radiation Oncology, Servier and Vivace Therapeutics and grant support from the Druckenmiller Foundation, the US Department of Defense and the LUNGevity Foundation. M.O. is also an uncompensated scientific advisory board member for the Mesothelioma Applied Research Foundation. M.G.Z. has received consulting fees from Vivace Therapeutics, MedImmune, Orion and Roche Diagnostics; honoraria for continuing medical education content from Physicians\u02bc Education Resource and HMP Global; and research funding to employer from MedImmune, Bristol Myers Squibb, Merck, Sapience, Werewolf, Vivace Therapeutics, GlaxoSmithKline, Epizyme, Polaris and Sellas Life Sciences. M.G.Z. is also Chair, Board of Directors, for the Mesothelioma Applied Research Foundation (uncompensated). R.K. has no disclosures. J.D. has consulting or advisory roles with BeiGene, Pierre Fabre, Bayer, GlaxoSmithKline, Merck KGaA, Boehringer Ingelheim, Roche\/Genentech, Daiichi-Sankyo Europe GmbH, Novartis, Pfizer, Ellipses Pharma, Axelia Oncology, Incyte and Amgen and has received institutional research funding from Roche, GlaxoSmithKline, Novartis, BeiGene, Bristol Myers Squibb, AstraZeneca, Amgen and Genentech. A.B. has research contracts (payment to institution) with Vivace Therapeutics, PMV Pharmaceuticals, Prelude Therapeutics, BeiGene, Hanmi Pharmaceuticals and Stingray Therapeutics and is an uncompensated advisory board member with Hanmi Pharmaceuticals. M.M. has consulting roles\/advisory board for AstraZeneca Australia Pty Ltd., Bayer Australia Pty Ltd., BeiGene Australia Pty Ltd., Bristol Myers Squibb Australia Pty Ltd., Eli Lilly Australia Pty Ltd., IQVIA Australia Pty Ltd. and The Limbic. A.W.T. has consulting roles with AbbVie, Aclaris Therapeutics, Affinia Therapeutics, Agenus, Asana Biosciences, Ascentage, Astex Pharmaceuticals, Axlmmune, Bayer, Bluprint Oncology, Compugen Ltd., Coretag Therapeutics, Daiichi-Sankyo, Day One Biopharmaceuticals, Exelixis, FibroGen, Gilde Healthcare Partners, HBM Partners, Horizon CME, IDEA Pharma, Ikena Oncology, Immuneering, Immunomet Therapeutics, Impact Therapeutics US, Indupro, Karma Oncology B.V., Kirilys Therapeutics, Lengo Therapeutics, Link Immunotherapeutics, Medicxi, Merck KGA, Mekanistic Therapeutics, Menarini Ricerche, Mersana, Mythic Therapeutics (Cytel), Nanobiotix, Nerviano Medical Sciences, Novo Nordisk, Novo Ventures, Nurix Therapeutics, Ocellaris Pharma & Eli Lilly, Partner Therapeutics, Pfizer, Pierre Fabre, Praxia Precision Medicines, Prelude Therapeutics, Pyramid Biosciences, Qualigen Therapeutics, Roche, RYVU Therapeutics, Seattle Genetics, Singzyme Pte Ltd., SK Life Science, SOTIO Biotechnology, Senti Biosciences, Sun Pharma Advanced Research Company (SPARC), Tensegrity Pharma, TheraTechnologies, Transcenta Therapeutics, Transgene, Trillium Therapeutics, Tubulis, Venus Oncology, Verastem Oncology, Vida Ventures Advisors and Voyant Bio (Ask Mendel AI, Inc.). A.W.T. also serves on advisory boards for Adagene, BioInvent, Boeringer Ingelheim International GmbH, Bright Peak Therapeutics, Cullinan Oncology, Curadev Pharma, Elucida Oncology, EMD Serono\/Merck KGaA, Hexagon Bio, Immunome, Jazz Pharmaceuticals, Kivu, Leerink, Mirati, NBE Therapeutics, Nested Therapeutics, Pheon Therapeutics, PYXIS Oncology, Roche, SPARC, Spirea Limited, Tagworks Pharmaceuticals, Vincerx, VRISE Therapeutics, Zentalis Pharmaceuticals and ZielBio. K.P.S.R. has consulting roles with AbbVie, AstraZeneca, Bayer, Daiichi-Sankyo, Eisai, Jazz Pharmaceuticals and Seagen and has received research funding or contracted research from AbbVie, AstraZeneca, Bayer, Daiichi-Sankyo, D3-Bio, Eisai, Genentech, Grail, Guardant Health, Hibercell, Innovent, Janssen, Merck, Seattle Genetics, UCB BioSciences and Xencor. A.T. is a consultant for Vivace Therapeutics. L.P. is the former Chief Scientific Officer for Vivace Therapeutics; has equity in Vivace Therapeutics; and is an advisor for Canaan Partners. F.A.D. is a consultant for Vivace Therapeutics. T.T.T. reports employment and stock incentives with Vivace Therapeutics. Y.L. reports employment and stock incentives with Vivace Therapeutics. N.S. reports employment and stock incentives with Vivace Therapeutics. H.L.K. has consultant\/advisory roles with AstraZeneca, Amgen, Enlaza and Vivace Therapeutics.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}